Drugs / Ipilimumab + nivolumab
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05200988 Background | Mar 2022 → Sep 2025 overdue | urinary bladder cancer, urothelial carcinoma | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ipilimumab + nivolumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05200988 ↗ |
| Route | Intravenous | “5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation” NCT05200988 ↗ |